RecruitingNCT06461533

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

Studying Acquired hemophilia A

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Takeda
Principal Investigator: Study Director
Takeda
Intervention: Susoctocog Alfa (Genetical Recombination)(drug)
Enrollment: 25 enrolled
Eligibility: All sexes
Timeline: 2024 – 2029

Study locations (1)

Takeda selected site, Tokyo, Tokyo, Japan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06461533 on ClinicalTrials.gov

Other trials for Acquired hemophilia A

Additional recruiting or active studies for the same condition.

RECRUITINGNCT06550882
A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea
Takeda
ACTIVE NOT RECRUITINGPHASE2NCT05345197
Emicizumab in Patients With Acquired Hemophilia A
University of Washington

See all trials for Acquired hemophilia A →

← Back to all trials